Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-06-03

Clinical Trial Update: Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ASF1057 for seborrheic dermatitis has completed, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ASF1057

Snippet

Sponsor: Astion Pharma A/S | Conditions: Seborrheic Dermatitis | Phase 3 | Status: COMPLETED